Since its introduction in 1977, percutaneous coronary intervention has become one of the
most commonly performed therapeutic procedures worldwide. Such widespread diffusion …

Coronary heart disease is an important source of mortality and morbidity among kidney
transplantation and liver transplantation candidates and recipients and is driven by …

The main causes of death in patients with chronic kidney disease (CKD) are of
cardiovascular nature. The interaction between traditional cardiovascular risk factors (CVRF) …

Percutaneous coronary interventions (PCI) are the mainstay of treating obstructive coronary
artery disease. However, procedural planning and individualization of the procedure is …

Due to age and impaired kidney function, older adults with kidney disease are at increased
risk of medication-related problems and related hospitalizations. One proa ctive approach to …

Background To identify and describe the use of the Grading of Recommendations,
Assessment, Development and Evaluation (GRADE) approach for rating the certainty of …

Shortening the duration of dual-antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) was shown to be effective and safe in patients at high bleeding risk (HBR) …

Purpose of review The evidence for use of dual antiplatelet therapy (DAPT) for patients
undergoing percutaneous coronary intervention (PCI) in the elective setting is relatively …

Background Conflicting evidence exists to support whether short duration of dual antiplatelet
therapy (DAPT) followed by P2Y12 inhibitor monotherapy reduces bleeding complications …

Background Dual antiplatelet therapy (DAPT) is currently the standard treatment for the
prevention of ischemic events after stent implantation. However, the optimal DAPT duration …